Revelation Biosciences (NASDAQ:REVB) Trading Down 6.7%

Revelation Biosciences, Inc. (NASDAQ:REVB)’s stock price was down 6.7% during trading on Wednesday . The stock traded as low as $0.94 and last traded at $0.99. Approximately 343,654 shares changed hands during trading, a decline of 93% from the average daily volume of 4,836,348 shares. The stock had previously closed at $1.06.

Revelation Biosciences Stock Down 2.2 %

The business’s 50 day moving average is $1.41 and its two-hundred day moving average is $2.06. The firm has a market cap of $1.43 million, a P/E ratio of -0.03 and a beta of 0.19.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings results on Friday, August 9th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.81) by $0.27. Equities research analysts anticipate that Revelation Biosciences, Inc. will post -12.46 EPS for the current year.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.